{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpes+Simplex+Virus&page=7",
    "query": {
      "condition": "Herpes Simplex Virus",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 293,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpes+Simplex+Virus&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpes+Simplex+Virus&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T02:41:41.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00566904",
      "title": "New Topical Treatment for Continued Pain After Shingles",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postherpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "Epikeia coatings with aspirin",
          "type": "DRUG"
        },
        {
          "name": "Epikeia coatings with lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Epikeia coatings alone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Biomedical Development Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-09",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2011-08-31",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00566904"
    },
    {
      "nct_id": "NCT01132716",
      "title": "Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Zoster",
        "Shingles",
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "Valacyclovir Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roxane Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2006-09",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132716"
    },
    {
      "nct_id": "NCT00222378",
      "title": "Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn's Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 129,
      "start_date": "2005-04",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-30",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222378"
    },
    {
      "nct_id": "NCT01321502",
      "title": "Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes"
      ],
      "interventions": [
        {
          "name": "famciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roxane Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 31,
      "start_date": "2007-07",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01321502"
    },
    {
      "nct_id": "NCT02571166",
      "title": "HSV529 Vaccine in HSV-2 Seropositive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex Virus 2"
      ],
      "interventions": [
        {
          "name": "HSV529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-11",
      "completion_date": "2018-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02571166"
    },
    {
      "nct_id": "NCT00116844",
      "title": "VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections, Herpesviridae"
      ],
      "interventions": [
        {
          "name": "Valaciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2005-03-29",
      "completion_date": "2006-01-10",
      "has_results": true,
      "last_update_posted_date": "2018-02-12",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 17,
      "location_summary": "Carmichael, California • Davis, California • Riverside, California + 13 more",
      "locations": [
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116844"
    },
    {
      "nct_id": "NCT04169009",
      "title": "Persistence of Protection by Shingrix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Zostavax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 105,
      "start_date": "2020-07-28",
      "completion_date": "2024-06-13",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04169009"
    },
    {
      "nct_id": "NCT00855309",
      "title": "Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "acyclovir sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 112,
      "start_date": "2008-11",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855309"
    },
    {
      "nct_id": "NCT00057330",
      "title": "HerpeVac Trial for Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8323,
      "start_date": "2003-01-14",
      "completion_date": "2009-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057330"
    },
    {
      "nct_id": "NCT04222985",
      "title": "Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "HSV 2 Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV 2 Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV 2 Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV 2 Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV 2 Formulation 5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV 2 Formulation 6",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride 0.9%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-02-18",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-10-10T02:41:41.550Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Boston, Massachusetts • Raleigh, North Carolina + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04222985"
    }
  ]
}